Trans ‘Treatments’ for Children One of the ‘Greatest Ethical Scandals in Medical History

Link to article…

The practice of sexually ‘transitioning’ children will be remembered as one of the “greatest ethical scandals in the history of medicine,” a report commissioned by French senators stated.

A landmark report produced at the behest of the centre-right Les Républicains in the French Senate found that the medical industry embarked upon the practice of giving children life-altering transgender treatments with little evidence of its effectiveness while ignoring the side effects.

The report found that while parents were often pressured by doctors to put their children on puberty-blocking drugs to prevent suicide, there is little proof that this course of action has any better outcomes for the child.

The head of the plastic surgery department at the Georges-Pompidou hospital in Paris, Laurent Lantieri told the report that there was “no evidence” that sex changes for children improved their quality of life because “there are obviously no randomized trials”.

Meanwhile, there was a prevalence of depression and other mental illnesses among children seeking to change their gender. The report found that 70 per cent of those seeking gender reassignment had “anxiety-depressive disorders” and 30 per cent had previously suffered some form of trauma, typically sexual abuse. Most disturbingly, 30 per cent of children seeking to change their gender were found to have been autistic, although they were often undiagnosed.

The evidence of the safety of prescribing puberty blockers to children was also “based on very fragile bases”, the report noted, pointing out that the justification for their administration in France was based on the so-called “Dutch Protocol” developed in the Netherlands two decades ago.

The protocol claimed that the effects of puberty-blocking drugs given to children as young as 12 years old were reversible. Yet, the French report said that this was not trustworthy, given that it was only based on the observation of 54 patients and was funded, in part, by Ferring Pharmaceuticals, a firm which produces puberty-blocking drugs.

Conversely, Denmark, Finland, Sweden, and the United Kingdom have all begun to restrict the use of puberty blockers given their side effects and often life-long impacts, which the report said indicated that the world is at a “turning point” on transgenderism.